These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

540 related articles for article (PubMed ID: 19238016)

  • 1. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.
    Hollyman D; Stefanski J; Przybylowski M; Bartido S; Borquez-Ojeda O; Taylor C; Yeh R; Capacio V; Olszewska M; Hosey J; Sadelain M; Brentjens RJ; Rivière I
    J Immunother; 2009; 32(2):169-80. PubMed ID: 19238016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simplified process for the production of anti-CD19-CAR-engineered T cells.
    Tumaini B; Lee DW; Lin T; Castiello L; Stroncek DF; Mackall C; Wayne A; Sabatino M
    Cytotherapy; 2013 Nov; 15(11):1406-15. PubMed ID: 23992830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.
    Oluwole OO; Davila ML
    J Leukoc Biol; 2016 Dec; 100(6):1265-1272. PubMed ID: 27354412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?
    Davila ML; Brentjens R
    Hematol Oncol Clin North Am; 2013 Apr; 27(2):341-53. PubMed ID: 23561477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
    Kochenderfer JN; Feldman SA; Zhao Y; Xu H; Black MA; Morgan RA; Wilson WH; Rosenberg SA
    J Immunother; 2009 Sep; 32(7):689-702. PubMed ID: 19561539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia.
    Lorentzen CL; Straten PT
    Scand J Immunol; 2015 Oct; 82(4):307-19. PubMed ID: 26099639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy.
    Lee JC; Hayman E; Pegram HJ; Santos E; Heller G; Sadelain M; Brentjens R
    Cancer Res; 2011 Apr; 71(8):2871-81. PubMed ID: 21487038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
    Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.
    Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Palomba ML; Halton E; Bernal Y; van Leeuwen DG; Sadelain M; Park JH; Brentjens RJ
    JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells.
    Stock S; Hoffmann JM; Schubert ML; Wang L; Wang S; Gong W; Neuber B; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
    Hum Gene Ther; 2018 Oct; 29(10):1167-1182. PubMed ID: 30024314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The severe cytokine release syndrome in phase I trials of CD19-CAR-T cell therapy: a systematic review.
    Jin Z; Xiang R; Qing K; Li X; Zhang Y; Wang L; Zhu H; Mao Y; Xu Z; Li J
    Ann Hematol; 2018 Aug; 97(8):1327-1335. PubMed ID: 29766234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.
    Geyer MB; Rivière I; Sénéchal B; Wang X; Wang Y; Purdon TJ; Hsu M; Devlin SM; Halton E; Lamanna N; Rademaker J; Sadelain M; Brentjens RJ; Park JH
    Mol Ther; 2018 Aug; 26(8):1896-1905. PubMed ID: 29910179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN-γ Production Profile.
    Magalhaes I; Kalland I; Kochenderfer JN; Österborg A; Uhlin M; Mattsson J
    J Immunother; 2018; 41(2):73-83. PubMed ID: 29315094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using gene therapy to manipulate the immune system in the fight against B-cell leukemias.
    Bouhassira DC; Thompson JJ; Davila ML
    Expert Opin Biol Ther; 2015 Mar; 15(3):403-16. PubMed ID: 25666545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD19-CAR trials.
    Ramos CA; Savoldo B; Dotti G
    Cancer J; 2014; 20(2):112-8. PubMed ID: 24667955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells.
    Singh H; Figliola MJ; Dawson MJ; Olivares S; Zhang L; Yang G; Maiti S; Manuri P; Senyukov V; Jena B; Kebriaei P; Champlin RE; Huls H; Cooper LJ
    PLoS One; 2013; 8(5):e64138. PubMed ID: 23741305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
    Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
    J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.